- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07950163
Paired Associative Stimulation of the Motor Cortex and the Dorsal Roots of the Cervical Spine for the Recovery of Arm and Hand Function in Chronic Middle Cerebral Artery Stroke. ASCLEPIUS Safety Evaluation Pilot Study (ASCLEPIUS)
Paired Associative Stimulation of the Motor Cortex and the Dorsal Roots of the Cervical Spine for the Recovery of Arm and Hand Function in Chronic Middle Cerebral Artery Stroke. ASCLEPIUS Safety Evaluation Pilot Study (Epidural Associative Stimulation of the Cerebral Cortex and Spinal Cord to Increase Plasticity in Upper Limb Stroke)
The goal of this pilot clinical trial is to learn whether paired associative stimulation (PAS) of the primary motor cortex and the cervical spinal dorsal roots, delivered through implanted epidural electrodes and combined with neurorehabilitation, is safe in adults with chronic paresis or paralysis of the arm and hand after a stroke in the territory of the middle cerebral artery.
The main question it aims to answer is:
* What adverse events occur during 12 months of follow-up with this treatment?
Secondary questions are whether the stimulation is feasible (whether pairing the corresponding electrode contacts of the motor cortex and the cervical spinal cord increases the motor response to stimulation) and whether it shows preliminary signs of efficacy on upper limb motor function, quality of life and caregiver burden.
Researchers will compare PAS plus rehabilitation with sham stimulation plus rehabilitation during a two-month double-blind phase.
Participants will:
- Have epidural electrodes surgically implanted over the primary motor cortex and the cervical spinal cord, connected to an implanted pulse generator
- Receive PAS or sham stimulation together with rehabilitation sessions for two months
- If assigned to sham stimulation, receive open-label PAS plus rehabilitation for a further two months
- Attend follow-up visits for 12 months
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Stroke in the territory of the middle cerebral artery (MCA) commonly leads to a chronic upper limb motor syndrome with loss of strength, reduced dexterity, abnormal synergies and spasticity. Paired associative stimulation (PAS) modulates synaptic connectivity following Hebbian principles: depending on the time interval between two paired stimuli, corticospinal connectivity can be strengthened or weakened. The hypothesis of this study is that invasive paired electrical stimulation of the primary motor cortex (M1) and the cervical spinal dorsal roots, applied together with neurorehabilitation, can be delivered without causing adverse effects by itself, and may produce a more consistent and longer-lasting effect than non-invasive approaches.
This is a single-center, prospective, randomized, controlled, two-phase pilot study (safety and exploratory therapeutic study) in 12 patients with chronic MCA stroke (6 experimental, 6 control), randomized 1:1 in balanced blocks of four.
All participants undergo surgery under general anesthesia. An epidural paddle lead (Artisan MRI Surgical Lead, Boston Scientific) is placed over M1, guided by intraoperative neurophysiology, and two epidural percutaneous leads (Linear Lead, Boston Scientific) are placed over the posterior aspect of the cervical spinal cord from spinal segments C3 to T1, as lateral as possible towards the dorsal roots of the affected side. Leads are initially externalized for postoperative neurophysiological studies (EMG responses to stimulation of each contact) so that cortical and cervical contacts acting on the same muscle groups can be paired. Within one week, the leads are tunneled and connected to an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific). The devices are CE-marked and are used in this study outside their intended purpose.
After a postoperative recovery period of about one month, the generator is programmed. In Phase I (two months, double-blind), the experimental group receives PAS and the control group receives sham stimulation (non-effective settings of the spinal lead that may produce a subjective sensation but no motor response), both combined with the same neurorehabilitation program (physiotherapy and occupational therapy, two or three sessions per week on alternate days). Stimulation settings are reviewed weekly. Participants and the outcome assessor are blinded; the neurosurgical team and the investigator who programs the device are not. In Phase II (two months, open-label), control group participants receive PAS plus rehabilitation.
Follow-up is identical in both groups: weekly during the two months of each stimulation phase, then monthly until month 6 and quarterly until month 12 after surgery. Brain MRI and neurophysiological assessment are performed before surgery, at the end of the stimulation period and at the end of follow-up. After 12 months, the system may be explanted if it provides no clinical benefit and according to the patient's wishes.
An independent Data Monitoring Committee reviews adverse events and other study data after the first patient and after the fourth patient complete their stimulation phase(s), before further patients are included.
Given the pilot nature and sample size, the analysis is descriptive and exploratory; no formal hypothesis test of efficacy is planned.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Juan Antonio Barcia Albacar
- Puhelinnumero: +34 917043744
- Sähköposti: jabarcia@ucm.es
Opiskelupaikat
-
-
-
Madrid, Espanja, 28040
- Hospital Clínico San Carlos
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Older than 18 and younger than 85 years of age.
- Single ischemic or hemorrhagic stroke with more than 6 months of evolution, with involvement of the hand and arm, that has shown no improvement with standard treatment after two previous reviews.
- No intercurrent strokes.
- Moderate functional impairment on the Fugl-Meyer Assessment for Upper Extremity (FMA-UE score 20 to 49).
- Good trunk control.
- Meets the safety requirements for imaging studies.
- Cooperative.
- Signed informed consent.
Exclusion Criteria:
- Severe disease or disorder (e.g., cancer, severe cardiac or respiratory disease, renal failure) or cognitive impairment (MoCA < 24), visual impairment or language impairment that could affect the ability to participate in a rehabilitation program.
- Presence of any previously implanted medical device.
- Severe claustrophobia.
- Major depression or any emotional disorder with a severe deficit of attention or cooperation that could cause difficulty in hand function.
- Modified Ashworth Scale score of 3 or higher.
Withdrawal criterion after enrollment: absence of evidence of partial preservation of the affected corticospinal tract on MRI tractography or neurophysiological testing (motor evoked potentials by transcranial magnetic stimulation).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Paired associative stimulation plus rehabilitation
Surgical implantation of an epidural lead over the primary motor cortex and two epidural leads over the cervical spinal cord, connected to an implanted pulse generator. During Phase I (2 months, starting about one month after surgery), participants receive paired associative stimulation (PAS) of the motor cortex and cervical dorsal roots during neurorehabilitation sessions (2 or 3 sessions per week). Stimulation settings are reviewed weekly. |
Paired associative stimulation (PAS) delivered through an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific) connected to an epidural lead over the primary motor cortex (Artisan MRI Surgical Lead) and two epidural leads over the cervical spinal cord, C3 to T1, placed laterally towards the dorsal roots of the affected side (Linear Lead). Cortical and cervical contacts that evoke responses in the same muscle group are paired, with an inter-stimulus delay derived from the EMG response latencies of each contact. Stimulus intensity is set immediately below the threshold for a motor response. Stimulation is applied during rehabilitation sessions and adjusted weekly for two months. The devices are CE-marked and used outside their intended purpose. Multidisciplinary neurorehabilitation program for the affected upper limb combining physiotherapy and occupational therapy, delivered two or three days per week on alternate days according to clinical status and tolerance, during the stimulation phases. The program is identical in both arms and is delivered by rehabilitation staff blinded to group allocation during Phase I. |
|
Huijausvertailija: Sham stimulation plus rehabilitation, then open-label PAS
Same surgical implantation as the experimental arm. During Phase I (2 months, starting about one month after surgery), participants receive sham stimulation (non-effective settings of the spinal lead that may produce paresthesia but no motor response) during the same neurorehabilitation program and visit schedule. After Phase I, participants enter Phase II (2 months, open-label) and receive paired associative stimulation (PAS) plus rehabilitation. |
Paired associative stimulation (PAS) delivered through an implanted 32-contact pulse generator (WaveWriter Alpha, Boston Scientific) connected to an epidural lead over the primary motor cortex (Artisan MRI Surgical Lead) and two epidural leads over the cervical spinal cord, C3 to T1, placed laterally towards the dorsal roots of the affected side (Linear Lead). Cortical and cervical contacts that evoke responses in the same muscle group are paired, with an inter-stimulus delay derived from the EMG response latencies of each contact. Stimulus intensity is set immediately below the threshold for a motor response. Stimulation is applied during rehabilitation sessions and adjusted weekly for two months. The devices are CE-marked and used outside their intended purpose. Multidisciplinary neurorehabilitation program for the affected upper limb combining physiotherapy and occupational therapy, delivered two or three days per week on alternate days according to clinical status and tolerance, during the stimulation phases. The program is identical in both arms and is delivered by rehabilitation staff blinded to group allocation during Phase I. Same implanted system as in the experimental arm. The pulse generator is programmed with settings that are not effective for inducing paired associative stimulation: stimulation of a single contact of the spinal lead with settings that produce paresthesia but no motor response. Sham stimulation is applied during rehabilitation sessions and reviewed weekly for two months, with the same visit schedule as the experimental arm. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Cumulative incidence of adverse events
Aikaikkuna: From surgery to 12 months after hospital discharge
|
Number of participants with adverse events, including those observed by the research team and those spontaneously reported by the participant, classified as serious or non-serious, by intensity (grades derived from CTCAE) and by causal relationship to the investigational device, the procedure or the stimulation. Expected undesired effects include pain, spasticity, muscle strength or sensation worse than at baseline, blocking of movements due to antagonist muscle contraction, worsening of hand dexterity and any other subjective intolerance. |
From surgery to 12 months after hospital discharge
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility: change in the amplitude of the motor response evoked by stimulation after paired associative stimulation
Aikaikkuna: Postoperative neurophysiological assessment, month 3 (end of Phase I), month 5 (end of Phase II, control group only) and month 12 after hospital discharge
|
Ability to produce an increase in the EMG motor response to single stimulation of the primary motor cortex or the cervical spinal cord after pairing the corresponding electrode contacts, compared with the response evoked without paired associative stimulation. |
Postoperative neurophysiological assessment, month 3 (end of Phase I), month 5 (end of Phase II, control group only) and month 12 after hospital discharge
|
|
Change in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Motor impairment of the affected upper limb. Total score ranges from 0 to 66; higher scores indicate better motor function. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
|
Change in Action Research Arm Test (ARAT) score
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Functional capacity of the affected upper limb (grasp, grip, pinch and gross movement). Total score ranges from 0 to 57; higher scores indicate better function. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
|
Change in Chedoke Arm and Hand Activity Inventory score
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Functional ability of the affected arm and hand in bilateral activities of daily living. Higher scores indicate greater functional independence. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
|
Change in Upper Limb Functional Index score
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Patient-reported functional status of the upper limb. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
|
Change in QuickDASH score
Aikaikkuna: Every 2 weeks during Phase I (month 1 + 2 weeks to month 3 after hospital discharge) and, in the control group only, every 2 weeks during Phase II (month 3 + 2 weeks to month 5)
|
Patient-reported upper limb disability and symptoms. Score ranges from 0 to 100; higher scores indicate greater disability. |
Every 2 weeks during Phase I (month 1 + 2 weeks to month 3 after hospital discharge) and, in the control group only, every 2 weeks during Phase II (month 3 + 2 weeks to month 5)
|
|
Change in Motor Activity Log (MAL) score
Aikaikkuna: Weekly during Phase I (month 1 + 1 week to month 3 after hospital discharge) and, in the control group only, weekly during Phase II (month 3 + 1 week to month 5)
|
Patient-reported amount and quality of use of the affected arm in daily activities. Item scores range from 0 to 5; higher scores indicate more and better use of the arm. |
Weekly during Phase I (month 1 + 1 week to month 3 after hospital discharge) and, in the control group only, weekly during Phase II (month 3 + 1 week to month 5)
|
|
Change in Modified Ashworth Scale (MAS) score
Aikaikkuna: Month 2 and month 3 after hospital discharge (Phase I) and, in the control group only, month 4 and month 5 (Phase II)
|
Spasticity of the affected upper limb. Scores range from 0 to 4; higher scores indicate greater spasticity. |
Month 2 and month 3 after hospital discharge (Phase I) and, in the control group only, month 4 and month 5 (Phase II)
|
|
Change in Modified Tardieu Scale (MTS)
Aikaikkuna: Month 1 (start of Phase I), month 3 (end of Phase I) and, in the control group only, month 5 (end of Phase II) after hospital discharge
|
Spasticity of the affected upper limb, assessed by the quality of the muscle reaction and the angle of muscle reaction to passive stretch. |
Month 1 (start of Phase I), month 3 (end of Phase I) and, in the control group only, month 5 (end of Phase II) after hospital discharge
|
|
Goal Attainment Scaling (GAS)
Aikaikkuna: Month 1, month 3, month 5 (control group only), month 6 and month 12 after hospital discharge
|
Attainment of individualized rehabilitation goals. Each goal is rated from -2 to +2; higher scores indicate better goal attainment. |
Month 1, month 3, month 5 (control group only), month 6 and month 12 after hospital discharge
|
|
Change in modified Rankin Scale (mRS) score
Aikaikkuna: Baseline (before surgery), month 6 and month 12 after hospital discharge
|
Global disability. Scores range from 0 (no symptoms) to 6 (death); higher scores indicate greater disability. |
Baseline (before surgery), month 6 and month 12 after hospital discharge
|
|
Change in perceived health-related quality of life (EuroQol 5D)
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Health-related quality of life perceived by the participant, measured with the EuroQol 5D questionnaire. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
|
Change in caregiver burden (reduced Zarit questionnaire)
Aikaikkuna: Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Burden of the main caregiver, measured with the reduced Zarit Burden Interview. Higher scores indicate greater burden. |
Baseline (before surgery), month 1 (start of Phase I), month 3 (end of Phase I), month 5 (end of Phase II, control group only), month 6 and month 12 after hospital discharge
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Juan Antonio Barcia Albacar, Servicio de Neurocirugía, Hospital Clínico San Carlos
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neurologiset ilmenemismuodot
- Aivoverenkiertohäiriöt
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Verisuonisairaudet
- Sydän-ja verisuonitaudit
- Patologiset prosessit
- Aivoinfarkti
- Aivojen iskemia
- Infarkti
- Nekroosi
- Iskemia
- Kallonsisäiset valtimotaudit
- Aivovaltimoiden sairaudet
- Aivoinfarkti
- Patologiset tilat, merkit ja oireet
- Merkit ja oireet
- Aivohalvaus
- Pareesi
- Infarkti, keskimmäinen aivovaltimo
- Terapeuttiset lääkkeet
- Potilashoito
- Terveyspalvelut
- Terveydenhuoltolaitokset työvoima ja palvelut
- Kuntoutus
- Jälkihoito
- Potilaan hoidon jatkuvuus
- Neurologinen kuntoutus
Muut tutkimustunnusnumerot
- 24/056-EC_P
- EC-NCR 01/23 ASCLEPIUS (Muu tunniste: Sponsor study code (Hospital Clínico San Carlos))
- IC 1439/25/EC-R (Muu tunniste: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS))
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .